期刊文献+

抗人DR5单克隆抗体对白血病U937细胞凋亡的作用 被引量:1

U937 cell apoptosis induced by anti-human DR5 monoclonal antibody(mDRA-6)
下载PDF
导出
摘要 目的:研究鼠抗人DR5单克隆抗体(mDRA-6)对白血病细胞U937的凋亡诱导作用。方法:光镜下观察mDRA-6作用后U937细胞的形态变化;流式细胞术检测U937细胞表面DR5表达率;MTT法检测mDRA-6对U937细胞生长的影响;An-nexinV-FITC/PI双染法流式细胞仪检测细胞凋亡率;琼脂糖凝胶电泳检测U937细胞DNA的片段化降解;JC-1单染流式细胞仪检测细胞线粒体膜电位改变。结果:mDRA-6作用U937细胞后呈现典型的细胞凋亡特征;MTT法检测显示mDRA-6作用U937细胞24小时死亡率为61·09%,并呈时间、浓度依赖性;流式细胞仪检测显示10mg/L的mDRA-6作用4小时,U937细胞凋亡率为79·12%;琼脂糖凝胶电泳显示DNA呈现明显梯状带型;mDRA-6作用U937细胞后线粒体膜电位明显下降。结论:mDRA-6能够诱导白血病U937细胞凋亡,是具有诱导细胞凋亡活性的功能性抗体。 Objective: To evaluate the effects of mouse anti-human DR5 monoclonal antibody (mDRA-6) on the apoptosis of leukemic cell U937.Methods: DR5 expression on leukemic cell surface was detected by flow cytometry with 366EC.The leukemic cell image following mDRA-6 (10 mg/L) treatment for 4 h was evaluated under microscope.The cytoxicity (FCM) induced by mDRA-6 in U937 cells was assayed with MTr method.The apoptosis of U937 after insulting by mDRA-6 (10 mg/L) for4 h or6 h was analyzed by FCM with AnnexinV-F ITC/PI staining and DNA ladder, respectively. Change of mitochondrial membrane potential was detected by FCM with JC-1 staining.Results: U937 cells treated with mDRA-6 (10 mg/L) exhibited typical apoptotic morphology.MTr analysis indicated that the death rate of U937 cells was 61.09% in the presence of 10 mg/L mDRA26 for 24 h.FCM detection indicated that the apoptosis rate of the cells was 79.12% in thre presence of 10 mg/L mDRA-6 for 4 h. Mitochondrial membrane potential declined in the presence of mDRA-6 for 4 h. Conclusion: mDRA-6 is a useful functional antibody with activity of inducing apoptosis of leukemic cell U937.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2008年第5期417-420,共4页 Chinese Journal of Immunology
基金 国家自然基金项目(No.30571697) 河南省杰出人才创新基金项目(No.074200510014)
关键词 DR5 单克隆抗体 白血病细胞 凋亡 DRS Monoclonal antibodies Leukemia cells Apoptosis
  • 相关文献

参考文献7

二级参考文献34

  • 1马远方,张军,赵粤萍,杨东亮,陈有海.肿瘤细胞对TRAIL敏感性与其表面DR5表达水平的相关性研究[J].中华肿瘤杂志,2004,26(9):528-530. 被引量:32
  • 2Ichikawa K,Liu W,Zhao L et al. Tumoricidal activity of a novel antihuman DR5 monoclonal antibody without hepatocyte cytotoxicity [J].Nat Med,2001 ,7(8) :954-960.
  • 3Heng, artner M O. The biochemistry of apoptosis [J]. Nature, 2000 ,(12) :4076.
  • 4Truneh A, Sharma S, Silverman C et al. Temperature-sensitive differential affinity of TRAIL for its receptors, DR5 is the highest affinity receptor [J]. J Biol Chem ,2000 ,275 (30) :23319-23325.
  • 5Yuanfang M,Yiguang C,Youhai C et al. Analysis of TRAIL receptor expression using a novel anti-TRAIL death receptor 5 monoclonal antibody [J]. CMJ ,2003 ,16:947-950.
  • 6Shigeno M ,Nakao K,Ichikawa T et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-KappaB inactivation [J]. Oneogene, 2003 , 22 : 1653-1662.
  • 7LaVallee T M ,Zhan X H,Johnson M S et al. 2-methoxyestradiol upregulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway [J]. Cancer Res,2003 ,63:468-475.
  • 8Wen J H ,Ramadevi N,Nguyen D et al. Antileukemic durgs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute lecukemia cells [J]. Blood ,2000 ,96(12) :3900-3906.
  • 9Wiley S R ,Schooley K,Smolak P J et al. Identification and characterization of a new member of the TNF family that induces apoptosis[J]. Immunity, 1995 ,3:673-682.
  • 10LeBlanc H N,Ashkenazi A. Apo2L/TRAIL and its death and decony recptots [J]. Cell Death Differ,2003 ,10:66-75.

共引文献53

同被引文献17

  • 1李淑莲,马远方,刘广超,张军,白慧玲,刘英杰.抗DR5单克隆抗体-mDRA-6对白血病细胞的凋亡诱导作用[J].细胞与分子免疫学杂志,2007,23(8):754-756. 被引量:5
  • 2Sarah S,Alexandre M,Olivier M. Regulating TRAIL receptor-induced cell death at the membrane:a deadly discussion[J].Recent Pat Anticancer Drug Discov,2011,(03):311-323.
  • 3Duiker E W,Mom C H,Jong S. The clinical trail of TRAIL[J].{H}EUROPEAN JOURNAL OF CANCER,2006.2233-2240.
  • 4Merino D,Lalaoui N,Morizot A. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2[J].{H}Molecular and Cellular Biology,2006.7046-7055.
  • 5Gaelle P,Valerie T,Stephane T. TRAIL receptor signaling and therapeutic option in bone tumors:the trap of the bone microenvironment[J].Am J Cancer Res,2012,(01):45-64.
  • 6Pennarun B,Meijer A,de Vries E G. Playing the DISC:turning on TRAIL death receptor-mediated apoptosis in cancer[J].{H}Biochimica et Biophysica Acta,2010,(02):123-140.
  • 7Walczak H,Haas T L. Biochemical analysis of the native TRAIL death-inducing signaling complex[J].{H}Methods in Molecular Biology,2008.221-239.
  • 8Koschny R,Walczak H,Ganten T M. The promise of TRAIL-potential and risks of a novel anticancer therapy[J].{H}Journal of Molecular Medicine,2007,(09):923-935.
  • 9Nadzeva GK,Denis L,Isabelle M. Targeted ovarian cancer treatment:the TRAILs of resistance[J].Am J Cancer Res,2012,(01):75-92.
  • 10Greco F A,Bonomi P,Craw ford J. Phase 2 study of mapatumumab,a fully human agonistic monoclonal antibody which target sand activates the TRAIL receptor1 inpatients with advanced nonsmall cell[J].{H}Lung Cancer,2008,(01):82-90.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部